infectious disease, clinical trials

In clinical trials, the new inoculation demonstrated greater protection for children and people older than 45 than the existing dengue vaccine.

Researchers say they’re abandoning the project in its current form—one of several that aims to induce what’s known as mucosal immunity against SARS-CoV-2.

Immunization had up to 77 percent efficacy in a Phase 2 clinical study of 450 children in Burkina Faso.

As COVID-19 therapies get emergency-use green lights, the Biden administration must organize a therapeutic review board to help identify what’s working and what’s not.

Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.

UPenn’s Katharine Bar discusses ongoing clinical trials to explore the efficacy of treating patients with plasma from individuals who have recovered from an infection.

Upon seeing pregnant women sick with COVID-19 at a University of Pennsylvania hospital, researchers there wrote trial protocols for blood transfusions to treat the disease that include expecting mothers.

The study showed that a vaccine combining a variety of immune-stimulating components was no more effective than a placebo.

Researchers aim to deploy the trial in neighboring Democratic Republic of Congo, which has been ravaged by Ebola for a year.

The study will examine the efficacy of four drugs—an antiviral and three monoclonal antibodies—that are already being used to treat patients in Democratic Republic of Congo.

T-cell therapies are not just for cancer. Researchers are also advancing immunotherapy methods to protect bone marrow transplant patients from viral infections. 

The Ebola drug increased survival in a small study, but the effect was not statistically significant.

Two new Ebola vaccine candidates prove safe and effective against the virus in macaques, a study shows.

A novel Ebola vaccine being tested in China is safe and provokes a notable immune response in people, according to a Phase 1 trial.

As the number of Ebola cases declines, Chimerix is unable to recruit enough patients for its trial in Liberia testing the antiviral drug brincidofovir.

The controversial antiviral drug earns better marks in the most recent analysis of the evidence. 

Ebola, MERS, and enterovirus D68; polio eradication efforts; new regulations on potentially dangerous research

Plasma-based therapy trials begin in West Africa; NIH-GSK vaccine shows promise in Phase 1; the real statistics

NIH admits new patient; joint pains stall clinical trial; U.S. grants immunity to vaccine developers; more